HIV shot could replace daily pills for those who skip doses

NCT ID NCT03635788

Ongoing Disease control Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested whether monthly injections of two HIV drugs (cabotegravir and rilpivirine) work better than daily oral pills for people with HIV who have a history of missing doses. Over 450 participants were enrolled. The goal was to see if the long-acting shots reduce the chance of treatment failure or viral rebound compared to standard daily pills.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Cabotegravir and Rilpivirine long-acting injectable
What this could lead to: If successful, this could offer a convenient monthly injection option for people with HIV who have trouble taking daily pills, improving viral control and reducing transmission risk.
What could go wrong: This is a phase 3 trial, but results are not yet published. The injectable regimen may still fail in some participants, and injection site reactions or other side effects could occur.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

HIV infectious disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HIV INFECTIONS

Contacts and locations

Locations

Alabama CRS

Birmingham, Alabama, 35294, United States
Brigham and Women's Hospital Therapeutics Clinical Research Site (BWH TCRS) CRS

Boston, Massachusetts, 02115, United States
Case Clinical Research Site

Cleveland, Ohio, 44106, United States
Chapel Hill CRS

Chapel Hill, North Carolina, 27599, United States
Cincinnati Clinical Research Site

Cincinnati, Ohio, 45219, United States
Columbia P&S CRS

New York, New York, 10032-3732, United States
Greensboro CRS

Greensboro, North Carolina, 27401, United States
Harbor-UCLA CRS

Torrance, California, 90502, United States
Houston AIDS Research Team CRS

Houston, Texas, 77030, United States
Jacobi Med. Ctr. Bronx NICHD CRS

The Bronx, New York, 10461, United States
Johns Hopkins University CRS

Baltimore, Maryland, 21205, United States
Massachusetts General Hospital CRS (MGH CRS)

Boston, Massachusetts, 02114, United States
New Jersey Medical School Clinical Research Center CRS

Newark, New Jersey, 07103, United States
Northwestern University CRS

Chicago, Illinois, 60611, United States
Ohio State University CRS

Columbus, Ohio, 43210, United States
Penn Therapeutics, CRS

Philadelphia, Pennsylvania, 19104, United States
Puerto Rico AIDS Clinical Trials Unit CRS

San Juan, 00935, Puerto Rico
Rush University CRS

Chicago, Illinois, 60612, United States
SUNY Stony Brook NICHD CRS

Stony Brook, New York, 11794, United States
The Miriam Hospital Clinical Research Site (TMH CRS) CRS

Providence, Rhode Island, 02906, United States
The Ponce de Leon Center CRS

Atlanta, Georgia, 30308-2012, United States
UCLA CARE Center CRS

Los Angeles, California, 90035, United States
UCSD Antiviral Research Center CRS

San Diego, California, 92103, United States
Ucsf Hiv/Aids Crs

San Francisco, California, 94110, United States
Univ. of Florida Jacksonville NICHD CRS

Jacksonville, Florida, 32209, United States
University of Colorado Hospital CRS

Aurora, Colorado, 80045, United States
University of Pittsburgh CRS

Pittsburgh, Pennsylvania, 15213, United States
University of Southern California CRS

Los Angeles, California, 90033-1079, United States
University of Washington AIDS CRS

Seattle, Washington, 98104-9929, United States
Vanderbilt Therapeutics (VT) CRS

Nashville, Tennessee, 37204, United States
Washington University Therapeutics (WT) CRS

St Louis, Missouri, 63110-1010, United States
Weill Cornell Chelsea CRS

New York, New York, 10010, United States
Weill Cornell Uptown CRS

New York, New York, 10065, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.